FPGEE common mistakes
FPGEE · Understand the traps and how to avoid them.
Computing pharmacokinetic parameters (half-life, clearance, Vd, AUC) from raw numbers without first writing the governing equation and checking unit consistency, so a value in mg is divided by a value in mcg/mL.
Candidates memorize formulas as strings of symbols and rush to plug in numbers under time pressure, treating unit conversion as an afterthought.
What to do instead
Before any calculation, write the equation, list each variable with its unit, and convert everything to a single system (mg, L, hr) in a scratch column. Sanity-check the answer against a known order of magnitude (e.g., a normal half-life in hours, not milliseconds).
Confusing zero-order and first-order elimination when asked about changes in half-life or time to steady state after a dose adjustment.
The two processes are memorized as parallel facts rather than as distinct mathematical behaviors (constant amount vs. constant fraction removed per unit time).
What to do instead
Anchor each concept to its signature: in first-order, half-life is dose-independent and steady state takes ~4-5 half-lives; in zero-order (e.g., phenytoin, ethanol at high concentrations), a small dose increase can produce a disproportionate, nonlinear rise in concentration. Practice predicting the direction of change before calculating.
Selecting a drug on the basis of a remembered indication without screening it against the patient's comorbidities, renal/hepatic function, pregnancy status, or interacting medications presented in the vignette.
Vignettes are read for the chief complaint only; candidates pattern-match "diagnosis to drug" and skip the rest of the stem, which is where the discriminating details live.
What to do instead
Adopt a fixed vignette-reading sequence: extract age, weight, pregnancy/lactation, renal and hepatic function, allergies, current medications, and abnormal labs into a short list before looking at the options, then eliminate any option that fails one of those constraints.
Applying the same starting dose or monitoring plan to special populations (elderly, pediatric, obese, dialysis, hepatic impairment) as to a general adult.
Dosing tables are studied for the standard adult and the adjustment rules are treated as optional trivia rather than as the core of the question.
What to do instead
For every pharmacotherapy question, explicitly ask "what is different about this patient?" and route through a mental checklist: weight-based vs. fixed dosing, renal dose adjustment, hepatic metabolism, Beers criteria for the elderly, and altered volume of distribution in obesity or ascites.
Answering drug-information questions by recalling the answer directly instead of identifying the appropriate tertiary, secondary, or primary source and the correct evaluation hierarchy.
Candidates conflate "what is the answer" with "how should this question be answered," and study drug facts while neglecting the structure of the literature.
What to do instead
Learn source categories by example: tertiary (compendia, DI databases, guidelines), secondary (indexing/abstracting services such as PubMed or Iowa Drug Information Service), primary (original research). When asked for the best resource, first classify the question type (dosing, compatibility, adverse event, primary literature) and match it to that tier.
Misreading a federal law question by mixing up which statute governs which activity - for example, treating the Poison Prevention Packaging Act, the Durham-Humphrey Amendment, the Kefauver-Harris Amendment, and the Combat Methamphetamine Epidemic Act as interchangeable.
The amendments are memorized as a list of names and years with weak linkage to the specific obligation each one creates for the pharmacist.
What to do instead
Build a statute-to-duty table with one column per law and one row per real task (child-resistant packaging, oral prescription status, proof of efficacy before marketing, PSE sales limits and logbooks, REMS, compounding oversight under 503A/503B). Test yourself by task, not by law name.
Treating compounding standards as optional best practice rather than as enforceable requirements, and answering questions about beyond-use dates, sterile technique, or prescription requirements from general intuition.
Compounding is often studied last and from summaries, so USP <795>/<797> categories, beyond-use dating logic, and the 503A vs. 503B distinction are fuzzy.
What to do instead
Memorize the framework rather than individual numbers: risk levels for sterile compounding (low, medium, high) with their corresponding beyond-use dates and environments, the water-source and purity requirements for nonsterile vs. sterile preparations, and the criteria that make a compound eligible for 503A (patient-specific prescription, licensed pharmacist, compliance with USP).
Answering pharmacoeconomic questions with a vague sense of cost rather than by classifying the analysis (cost-minimization, cost-effectiveness, cost-utility, cost-benefit, cost-of-illness) and identifying its outcome unit.
The types are memorized as similar-sounding names without the outcome-unit discriminator that actually defines them.
What to do instead
Attach each type to its outcome: dollars only (cost-minimization), natural clinical units such as mm Hg or life-years gained (cost-effectiveness), quality-adjusted life-years (cost-utility), and dollar-valued outcomes with a net benefit or benefit-to-cost ratio (cost-benefit). Read the denominator of the ratio in the question stem first - it usually names the analysis outright.
Interpreting a study result as clinically meaningful without checking the confidence interval, absolute rather than relative risk reduction, number needed to treat, and whether the endpoint was a surrogate or a hard outcome.
Headlines and abstract conclusions emphasize relative risk and p-values, and candidates carry that framing into the exam.
What to do instead
For every study question, compute or compare absolute risk reduction (control rate minus treatment rate) and NNT (1/ARR) alongside the relative reduction, and check whether the confidence interval crosses the null. Flag any endpoint that is a lab value or biomarker rather than mortality, stroke, or hospitalization.
Missing questions on mechanism and structure-activity relationships because drugs are memorized by name and class rather than by target, functional group, and metabolic soft spot.
Medicinal chemistry is treated as rote nomenclature, so questions that present an unfamiliar structure or ask why a structural change alters potency, duration, or toxicity have no scaffold to hang on.
What to do instead
Study each class around a core pharmacophore: identify the target (receptor, enzyme, transporter), the key binding or reactive groups, and the metabolic or excretion route that drives duration and interactions. Practice predicting the consequence of a single structural change (adding a hydroxyl, replacing a methyl, halogenating an aromatic ring) on lipophilicity, half-life, and receptor affinity before looking at the answer choices.